Aradigm Receives Complete Response Letter from the FDA for Linhaliq NDA

HAYWARD, Calif.–(BUSINESS WIRE)–Jan. 29, 2018– Aradigm Corporation (NASDAQ: ARDM) (the “Company”)today announces that it received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its New Drug…Original Article